A Combined Phase 0/2 "Trigger" Trial of Niraparib in Combination with Radiation in Patients with NewlyDiagnosed Glioblastoma

W. R. Kennedy,T. Margaryan, J. Molloy, W. Knight, J. Harmon, A. Hong, J. Wanebo, K. Braun,M. A. Garcia,I. J. Barani,W. Yoo,A. C. Tien, A. Tovmasyan,S. Mehta,N. Sanai

International journal of radiation oncology, biology, physics（2023）

引用 0|浏览4

暂无评分

摘要

Niraparib achieves pharmacologically-relevant concentrations in non-enhancing, newly-diagnosed GBM tissue in excess of any other studied PARP inhibitor. When delivered with concurrent RT, niraparib was well-tolerated, with low rates of grade 3+ toxicity. Initial clinical efficacy data are encouraging.

查看译文

关键词

glioblastoma,niraparib,radiation,newly-diagnosed

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要